RSS-Feed abonnieren
DOI: 10.1055/s-0038-1645192
Dilute aPTT Prolongation by Antiphospholipid Antibodies in Patients with Liver Cirrhosis
Publikationsverlauf
Received 11. April 1989
Accepted after revision 15. November 1989
Publikationsdatum:
02. Juli 2018 (online)
Summary
The behaviour of aPTT, as assessed by standard or diluted phospholipid mixture, was investigated in 20 patients suffering from liver cirrhosis. Standard aPTT was prolonged in 13 but it was corrected by 1:1 mixture with normal plasma. Dilute aPTT performed in samples mixed 1:1 with normal plasma and calculated by the difference in time between 1:80 and 1:5 phospholipid mixture was prolonged in 9 patients, who had also significantly higher titre of anticardiolipin antibodies (p <0.005). Unlike patients’ plasma with normal dilute aPTT, the addition of 0.05 M PC/PS liposomes to patient’s plasma with prolonged dilute aPTT significantly shortened dilute aPTT (p <0.001).
This study shows the presence of antiphospholipid antibodies in some patients with liver cirrhosis; this seems to be responsible for the prolongation of dilute aPTT.
-
References
- 1 Flute PT. Clotting abnormalities in liver diseases. Prog Liver Dis 1977; 16: 301-311
- 2 Cordova C, Musca A, Violi F, Alcssandri C, Ferro D, Piromalli A, Balsano F. Prekallikrcin behaviour in chronic active hepatitis and in cirrhotic patients. Haemostasis 1984; 14: 218-222
- 3 Coccheri S, Mannucci PM, Palareti G, Gervasoni W, Poggi M, Vigano S. Significance of plasma fibrinopeptidc A and high molecular weight fibrinogen in patients with liver cirrhosis. Rr J Haematol 1982; 52: 503-509
- 4 Cordova C, Violi F, Alessandri C, Musca A, Balsano F. Low doses of calcium-hcparin in liver cirrhosis. Thromb Haemostas 1985; 54: 551
- 5 Francis jr BB, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver cirrhosis. Haemostasis 1984; 14: 460-466
- 6 Cordova C, Violi F, Alessandri C, Ferro D, Saliola M, Musca A, Balsano F. Prekallikrcin and factor VII as prognostic indexes of liver failure. Am J Clin Pathol 1986; 85: 579-582
- 7 Biland L, Duckcrt F, Prisender S, Nyman D. Quantitative estimation of coagulation factors in liver disease.The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb Haemostas 1978; 39: 646-656
- 8 Martinez J, Poloscak JE. Haemostatic alterations in liver diseases. In: Hepatology, a Textbook of Liver Disease Zakim D, Bayer TD. (eds) W B Saunders; Philadelphia: 1982. pp 546-580
- 9 Violi F, Ferro D, Valesini G, Quintarelli C, Balsano F. Lupus anticoagulant in liver cirrhosis. Thromb Haemostas. 1988; 59: 335
- 10 Violi F, Valesini G, Ferro D, Tincani A, Balestrieri G, Balsano F. Anticoagulant activity of anticardiolipin antibodies. Thromb Res 1985; 44: 543-548
- 11 Alving BM, Baldwin PE, Richards RL, Jackson BJ. The dilute phospholipid aPTT: A sensitive assay for the verification of lupus anticoagulants. Thromb Haemostas 1985; 54: 709-712
- 12 Harris EN, Gharavi AE, Patel SP, Hughes GR V. Evaluation of anticardiolipin antibody test: report of an international workshop held April 4, 1986. Clin Exp Immunol 1987; 68: 215-222
- 13 Harris EN, Loizou S, Englert H. Anticardiolipin antibodies and lupus anticoagulant. Lancet II 1984; 1099
- 14 Harris EN, Gharavi AE, Tincani A, Chan JK H, Englert H, Mantelli P, Allegro F, Balestrieri G, Hughes GR V. Affinity purified anti-DNA antibodies. J Clin Immunol 1985; 17: 155-162
- 15 Triplett DA, Brandt JT, Musgarave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259: 550-554
- 16 Thiagaraian P, Shapiro SS. Lupus Anticoagulants. In: Disorder of Thrombin Formation Colman RW. (ed) Churchill Livingstone; New York: 1984. pp 101-108
- 17 Lechner K, Pabinger-Fasching I. Lupus anticoagulants and thrombosis. Haemostasis 1985; 15: 254-262
- 18 Mannucci PM, Canciani MT, Mari D, Meucci P. The varied sensitivity of partial thromboplastin and prothrombin time reagents in demonstration of lupus-like anticoagulant. Scand J Haematol 1979; 22: 423-432
- 19 Rosove MH, Ismail M, Koziol BJ, Runge A, Kasper CK. Lupus Anticoagulant: improved diagnosis with a Kaolin clotting time using rabbit brain phospholipid in standard and high concentration. Blood 1986; 68: 472-8
- 20 Elias M, Eldor A. Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Arch Intern Med 1984; 144: 510-515
- 21 Valesini G, Barnaba V, Franco A, Levrero M, Cauda R, Laghi V, Balsano F. Antiphospholipid antibodies in chronic active hepatitis: lack of correlation with anti-DNA antibodies. Protides Biol Fluids 1985; 33: 365-368
- 22 Boey HL, Colaco CB, Gharavi AE, Elkon KB, Loizou F, Hughes GR V. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res) 1983; 287: 1021-1023
- 23 Hamsten A, Norberg R, Bjorkolm R, De Faire V, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113-116
- 24 Kamisasa I, Hidai K, Sugiura H, Wanda T, Yamanaka M. Effects of splenectomy on blood coagulation and fibrinolysis in patients with liver cirrhosis: possible role of the spleen in haemostasis. Thromb Haemostas 1979; 42: 1529-1535
- 25 Oka K, Tanaka K. Intravascular coagulation in autopsy cases with liver disease. Thromb Haemostas 1979; 42: 564-570